SamanTree Medical, a Lausanne, Switzerland-based cancer surgery company, closed a CHF 9.5m Series A financing.
The round was led by Panakès Partners, alongside the Sioux Tech Fund, the venture arm of Sioux Technologies, with participation from BOM Brabant Ventures and btov Partners. In conjunction with the funding, Fabrizio Landi, Managing Partner at Panakès, former General Manager and one of the founders of Esaote Medical Imaging, joined SamanTree’s board, along with Arnoud de Geus, Director of New Business Development at Sioux.
The company intends to use the funds to commercialize the patented Histolog™ system, notably the recently CE mark Histolog™ Scanner v2, for enabling precise tumor removal at first surgery.
Founded in December 2014 by CEO Bastien Rachet as a spin-off company from the Swiss Federal Institute of Technology (EPFL), SamanTree Medical develops imaging modalities and data analytic solutions for improving cancer treatment care.
Its Histolog™ enables a global mapping of a lumpectomy for full margin control with histology-grade confidence in few minutes before closing the incision. With this imaging modality, the clinician is one touch-on-the-screen away from visualizing cancerous cell on a surgical specimen immediately during surgery.